Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab + MP in CRPC
NCT00770848Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2008
- Primary completion
- Jan 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 2 trial of rilotumumab in castration-resistant prostate cancer (CRPC), sponsored by Amgen. Started Nov 2008; status: completed.
02
Drugs
rilotumumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00770848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770848.